VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June 30, 2015.
Recent key corporate and clinical developments include:
• Reported record patient enrollment numbers in April with 31 patients, 26 patients in May and 25 patients in June in the Phase 3 head and neck cancer trial.
Help employers find you! Check out all the jobs and post your resume.
Recent key corporate and clinical developments include:
• Reported record patient enrollment numbers in April with 31 patients, 26 patients in May and 25 patients in June in the Phase 3 head and neck cancer trial.
Help employers find you! Check out all the jobs and post your resume.
